521070-97-3Relevant academic research and scientific papers
Melanin-concentrating hormone receptor 1 antagonists. Synthesis and structure-activity relationships of novel 3-(aminomethyl)quinolines
Kamata, Makoto,Yamashita, Toshiro,Imaeda, Toshihiro,Tanaka, Toshio,Masada, Shinichi,Kamaura, Masahiro,Kasai, Shizuo,Hara, Ryoma,Sasaki, Shigekazu,Takekawa, Shiro,Asami, Asano,Kaisho, Tomoko,Suzuki, Nobuhiro,Ashina, Shuntaro,Ogino, Hitomi,Nakano, Yoshihide,Nagisa, Yasutaka,Kato, Koki,Kato, Kaneyoshi,Ishihara, Yuji
experimental part, p. 2353 - 2366 (2012/05/05)
It was found that 3-(aminomethyl)quinoline derivatives showed high binding affinities for melanin-concentrating hormone receptor 1 (MCHR1) with reduced affinity for serotonin receptor 2c (5-HT2c) when the dihydronaphthalene nucleus of compound 1 (human MCHR1, IC50 = 1.9 nM; human 5-HT2c receptor, IC50 = 0.53 nM) was replaced by other bicyclic core scaffolds. Among the synthesized compounds, 8-methylquinoline derivative 5v especially showed high binding affinity (IC50 = 0.54 nM), potent in vitro antagonistic activity (IC50 = 2.8 nM) for MCHR1, and negligible affinity for 5-HT2c receptor (IC50 > 1000 nM). Oral administration of 5v significantly and dose-dependently suppressed nocturnal food intake in diet-induced obese rats and did not affect food intake in MCHR1-deficient mice. These results and rat pharmacokinetic study findings suggested that compound 5v is a highly potent, orally bioavailable, and centrally acting nonpeptide MCHR1 antagonist.
QUINOLINE COMPOUND
-
Page 98, (2010/02/08)
A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula: wherein Aris a cyclic group optionally having substituent(s) ;Xis a bond or a spacer having a main chain of 1 to 6 atoms;R1 and R2are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R1 and R2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s);Yis a divalent hydrocarbon group optionally having substituent(s) (except CO);R3is a hydrogen atom or a hydrocarbon group optionally having substituent(s); andring A and ring Bmay further have substituents, and when ring B further has a substituent, the substituent may be linked to R1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.
